CU23608A3 - Vacuna para la tuberculosis ureasa deficiente con eficacia mejorada - Google Patents

Vacuna para la tuberculosis ureasa deficiente con eficacia mejorada

Info

Publication number
CU23608A3
CU23608A3 CU20050206A CU20050206A CU23608A3 CU 23608 A3 CU23608 A3 CU 23608A3 CU 20050206 A CU20050206 A CU 20050206A CU 20050206 A CU20050206 A CU 20050206A CU 23608 A3 CU23608 A3 CU 23608A3
Authority
CU
Cuba
Prior art keywords
deficient
nucleic acid
tuberculosis
acid molecules
ureasa
Prior art date
Application number
CU20050206A
Other languages
English (en)
Inventor
Juergen Hess
Baerbel Raupach
Stefan H E Kaufmann
Leander Grode
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of CU23608A3 publication Critical patent/CU23608A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a nuevas vacunas recombinantes deficientes en ureasa que proporcionan inmunidad protectora contra la tuberculosis. Adicionalmente, la presente invención se refiere a nuevas moléculas de ácido nucleico recombinante, vectores que contiene dichas moléculas de ácido nucleico, células transformadas con dichas moléculas de ácido nucleico y polipéptidos codificados por dichas moléculas de ácido nucleico.
CU20050206A 2003-04-23 2005-10-26 Vacuna para la tuberculosis ureasa deficiente con eficacia mejorada CU23608A3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46464403P 2003-04-23 2003-04-23

Publications (1)

Publication Number Publication Date
CU23608A3 true CU23608A3 (es) 2010-12-08

Family

ID=33310924

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20050206A CU23608A3 (es) 2003-04-23 2005-10-26 Vacuna para la tuberculosis ureasa deficiente con eficacia mejorada

Country Status (24)

Country Link
US (2) US7988980B2 (es)
EP (1) EP1618128B1 (es)
JP (1) JP4662925B2 (es)
KR (1) KR101101263B1 (es)
CN (1) CN1798762B (es)
AT (1) ATE473238T1 (es)
AU (1) AU2004232485B2 (es)
BR (1) BRPI0409789B8 (es)
CA (1) CA2523084C (es)
CU (1) CU23608A3 (es)
CY (1) CY1110793T1 (es)
DE (1) DE602004028000D1 (es)
DK (1) DK1618128T3 (es)
ES (1) ES2344698T3 (es)
HK (1) HK1091217A1 (es)
HR (1) HRP20100395T1 (es)
MX (1) MXPA05011360A (es)
PL (1) PL1618128T3 (es)
PT (1) PT1618128E (es)
RU (1) RU2342400C2 (es)
SI (1) SI1618128T1 (es)
UA (1) UA91180C2 (es)
WO (1) WO2004094469A1 (es)
ZA (1) ZA200508276B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101101263B1 (ko) * 2003-04-23 2012-01-04 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 개선된 효능을 갖는 결핵 백신
EP1649869A1 (en) * 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
WO2007058663A2 (en) 2004-12-01 2007-05-24 Aeras Global Tb Vaccine Foundation Recombinant bcg strains with enhanced ability to escape the endosome
CN101969976A (zh) * 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 针对分枝杆菌的多肽疫苗和接种策略
WO2011031139A1 (en) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
WO2012026820A2 (en) 2010-08-27 2012-03-01 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
PL3360569T3 (pl) * 2010-09-20 2020-07-27 Vakzine Projekt Management Gmbh Rekombinowane Mycobacterium jako szczepionka do stosowania u ludzi
AR083829A1 (es) 2010-11-10 2013-03-27 Leti S L Unipersonal Lab Coadyuvante con potencialidad inmunogenica incrementada
HUE027781T2 (en) 2010-12-21 2016-11-28 Max-Planck-Gesellschaft Zur Foerderung Der Wss E V Determination of the effectiveness of vaccination against live recombinant mycobacteria
SG191332A1 (en) * 2010-12-21 2013-07-31 Max Planck Gesellschaft Recombinant mycobacterium as a vaccine
RU2520078C1 (ru) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
EP3090757A1 (en) * 2015-05-04 2016-11-09 Vakzine Projekt Management GmbH Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
EP3349790A1 (en) 2015-09-18 2018-07-25 Rijksuniversiteit Groningen Long chain inulin for stimulating an immune response
KR101825439B1 (ko) * 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
JP7035063B2 (ja) * 2017-04-07 2022-03-14 ジュン・リウ ｐｈｏＰ－ｐｈｏＲを過剰発現する組換えＢＣＧ
US10496469B2 (en) * 2017-07-25 2019-12-03 Aurora Labs Ltd. Orchestrator reporting of probability of downtime from machine learning process
RU2678175C1 (ru) * 2018-03-16 2019-01-23 федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) Рекомбинантный штамм вируса гриппа A/PR8/HK-NS80E85A, экспрессирующий фрагменты антигенов ESAT-6 и Ag85A M.tuberculosis, для получения векторной вакцины против туберкулеза
CN111979162B (zh) * 2019-05-22 2024-02-13 上海市公共卫生临床中心 重组卡介苗菌株、其制备方法和用途
EP4149529A1 (en) 2020-05-11 2023-03-22 Vakzine Projekt Management GmbH Prevention of infectious diseases by modulating the immune system
WO2021228363A1 (en) 2020-05-11 2021-11-18 Vakzine Projekt Management Gmbh Prevention of infectious diseases by modulating the immune system
EP4122491A1 (en) 2021-07-22 2023-01-25 Vakzine Projekt Management GmbH Recombinant microbacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma
IL310225A (en) 2021-07-22 2024-03-01 Serum Life Science Europe Gmbh Recombinant MYCOBACTERIUM as an immunotherapeutic agent for the second-line treatment of bladder carcinoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0902086A1 (en) 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
KR101101263B1 (ko) * 2003-04-23 2012-01-04 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 개선된 효능을 갖는 결핵 백신

Also Published As

Publication number Publication date
CA2523084A1 (en) 2004-11-04
CY1110793T1 (el) 2015-06-10
EP1618128A1 (en) 2006-01-25
AU2004232485B2 (en) 2009-11-26
JP2007524367A (ja) 2007-08-30
US7988980B2 (en) 2011-08-02
US8545854B2 (en) 2013-10-01
PL1618128T3 (pl) 2010-12-31
ATE473238T1 (de) 2010-07-15
AU2004232485A1 (en) 2004-11-04
DE602004028000D1 (de) 2010-08-19
WO2004094469A1 (en) 2004-11-04
US20070134267A1 (en) 2007-06-14
RU2342400C2 (ru) 2008-12-27
KR101101263B1 (ko) 2012-01-04
KR20050114281A (ko) 2005-12-05
PT1618128E (pt) 2010-10-13
SI1618128T1 (sl) 2010-11-30
RU2005136354A (ru) 2006-03-20
EP1618128B1 (en) 2010-07-07
US20120027794A1 (en) 2012-02-02
CN1798762B (zh) 2010-04-28
JP4662925B2 (ja) 2011-03-30
CN1798762A (zh) 2006-07-05
BRPI0409789B8 (pt) 2021-05-25
MXPA05011360A (es) 2005-11-28
BRPI0409789A (pt) 2006-05-30
DK1618128T3 (da) 2010-10-18
CA2523084C (en) 2012-09-04
HK1091217A1 (en) 2007-01-12
HRP20100395T1 (hr) 2010-09-30
ZA200508276B (en) 2006-06-28
ES2344698T3 (es) 2010-09-03
UA91180C2 (ru) 2010-07-12
BRPI0409789B1 (pt) 2018-10-16

Similar Documents

Publication Publication Date Title
CU23608A3 (es) Vacuna para la tuberculosis ureasa deficiente con eficacia mejorada
CY1106350T1 (el) Εμβολιο φυματιωσης
CR9443A (es) Vacuna de toxoide de c. perfringens alfa
AR092712A1 (es) Una proteina con actividad cetosa 3-epimerasa
BR112018008766A2 (pt) variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos
EP1824971A4 (en) GENETICALLY MODIFIED CLOSTRIDIENGENES, PROTEINS CODED BY THE CHANGED GENES AND THEIR USES
WO2007024947A3 (en) Canine influenza vaccines
BRPI0410031A (pt) variantes fc otimizadas e métodos para sua geração
HK1142809A1 (en) Multimeric multiepitope influenza vaccines
MX2010005589A (es) Composicion para el cuidado personal.
CO6331298A2 (es) Vacunas contra coccidiosis
EA201000327A1 (ru) Белок
MY150226A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use
BRPI0821240B8 (pt) formas mutantes de estreptolisina o
AR102950A1 (es) Variantes de lipasa y polinucleótidos que las codifican
BR0011469A (pt) Gm-csf equina
AR052947A1 (es) Polipeptidos que tienen actividad antimicrobiana y polinucleotidos que codifican para los mismos
BR0308180A (pt) protéinas de superfìcie de leptospira
BR0013574A (pt) Antìgeno vacina de moraxella
MX2010008170A (es) Vacunas para influenza canina.
DE60324285D1 (de) Immunmodulatorische konstrukte und deren verwendungen
WO2004087888A3 (en) Neurotransmitter signaling can regulate life span in c. elegans
ITVR20040049A1 (it) Elemento di protezione per cassoni di veicoli indstriali
AR073595A1 (es) Vacunas que contienen variantes geneticas de parvovirus canino
ES2172482B1 (es) Adicion de la patente es200100402 "vacuna para la proteccion de perros frente a la leishmania".

Legal Events

Date Code Title Description
FG Grant of patent